Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
moxifloxacin + meropenem
- Development stage
- Preclinical
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination antibiotic regimen consisting of moxifloxacin (a fluoroquinolone antibiotic) and meropenem (a carbapenem antibiotic). This combination provides broad-spectrum antimicrobial coverage and has been studied for the treatment of severe sepsis and septic shock. Clinical trials have shown that the combination does not provide significant advantages over meropenem monotherapy in reducing organ failure or mortality in patients with severe sepsis.
- Brand names
- AveloxMoxezaVigamox
- Other names
- none
02
Targets
PBP (Penicillin-binding protein family)Topo IV (Bacterial Topoisomerase IV)DNA gyrase
Beyond the preview
Go deeper on moxifloxacin + meropenem.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on moxifloxacin + meropenem.